Sign in
CompletedNo phase

Intraoperative Dexmedetomidine Use, MMP-8, and Postoperative Delirium After Cardiac Surgery With Cardiopulmonary Bypass

Key facts

Who runs it
Shusheng Li
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
5,688 people enrolled
Started
1 Apr 2023
Ended
15 Oct 2024
Type of study
Observational, 4 groups
Treatments tested
  • Dexmedetomidine
Record updated
9 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Adults aged 18 years or older
  • Patients undergoing cardiac surgery with cardiopulmonary bypass (CPB)
  • For the retrospective cohort, eligible patients undergoing cardiac surgery with CPB at the three participating campuses of Tongji Hospital between January 2015 and December 2022
  • For the prospective biomarker cohort, eligible participants enrolled between April 2023 and September 2024 with archived plasma samples collected preoperatively, at the end of surgery, and 24 h postoperatively, together with linked clinical data

Who cannot take part

  • Emergency surgery
  • Conditions precluding dexmedetomidine use, including second- or third-degree atrioventricular block without a pacemaker, uncontrolled hypotension, acute cerebrovascular disease, or known hypersensitivity to dexmedetomidine
  • Severe neurological or psychiatric disorders, including a history of treatment for severe mental illness
  • Inability to communicate effectively because of severe hearing, visual, or speech impairments
  • Pregnancy or breastfeeding

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This observational study evaluated the association between intraoperative dexmedetomidine use and postoperative delirium (POD) in adults undergoing cardiac surgery with cardiopulmonary bypass (CPB). The study included two linked clinical components. First, routinely collected clinical data from patients undergoing cardiac surgery with CPB at three campuses of Tongji Hospital between January 2015 and December 2022 were analyzed to evaluate the dexmedetomidine-POD association. Second, perioperative plasma samples and clinical data from a prospective observational cohort enrolled between April 2023 and September 2024 were used to characterize perioperative matrix metalloproteinase-8 (MMP-8) dynamics and their associations with intraoperative dexmedetomidine use and POD. Dexmedetomidine administration was determined by the attending anesthesiologist according to clinical judgment and routine anesthetic practice and was not assigned by the study protocol.

The 4 groups in the trial

  • Retrospective Cohort - Dexmedetomidine Exposed

    Patients in the retrospective multicampus cohort who underwent cardiac surgery with cardiopulmonary bypass between January 2015 and December 2022 and received intraoperative dexmedetomidine by continuous intravenous infusion as part of routine anesthetic care. Dexmedetomidine administration was determined by the attending anesthesiologist according to clinical judgment and was not assigned by the study protocol.

    Treatment: Dexmedetomidine

  • Retrospective Cohort - No Dexmedetomidine Exposure

    Patients in the retrospective multicampus cohort who underwent cardiac surgery with cardiopulmonary bypass between January 2015 and December 2022 and did not receive intraoperative dexmedetomidine.

  • Prospective Cohort - Dexmedetomidine Exposed

    Participants in the previously established prospective observational cohort who underwent cardiac surgery with cardiopulmonary bypass between April 2023 and September 2024 and received intraoperative dexmedetomidine as part of routine anesthetic care. Dexmedetomidine use was determined by the treating anesthesiologist and was not influenced by the study investigators. Archived perioperative plasma samples from these participants were used for the present MMP-8 analyses.

    Treatment: Dexmedetomidine

  • Prospective Cohort - No Dexmedetomidine Exposure

    Participants in the previously established prospective observational cohort who underwent cardiac surgery with cardiopulmonary bypass between April 2023 and September 2024 and did not receive intraoperative dexmedetomidine. Archived perioperative plasma samples from these participants were used for the present MMP-8 analyses.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Association of Intraoperative Dexmedetomidine Use and Perioperative Plasma MMP-8 Dynamics With Postoperative Delirium in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass
Record updated
9 September 2026